NASDAQ:EPIX ESSA Pharma (EPIX) Stock Price, News & Analysis → Biggest hedge fund manager has huge warning for U.S. dollar (From Stansberry Research) (Ad) Free EPIX Stock Alerts $6.24 -0.01 (-0.16%) (As of 04:29 PM ET) Add Compare Share Share Today's Range$5.84▼$6.4050-Day Range$6.08▼$9.4752-Week Range$2.58▼$11.67Volume49,159 shsAverage Volume125,287 shsMarket Capitalization$276.06 millionP/E RatioN/ADividend YieldN/APrice Target$16.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ESSA Pharma alerts: Email Address ESSA Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside176.4% Upside$16.50 Price TargetShort InterestBearish2.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-1.00Based on 3 Articles This WeekInsider TradingSelling Shares$16,566 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.80) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.76 out of 5 starsMedical Sector593rd out of 915 stocksPharmaceutical Preparations Industry276th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingESSA Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageESSA Pharma has received no research coverage in the past 90 days.Read more about ESSA Pharma's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.09% of the outstanding shares of ESSA Pharma have been sold short.Short Interest Ratio / Days to CoverESSA Pharma has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in ESSA Pharma has recently increased by 20.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldESSA Pharma does not currently pay a dividend.Dividend GrowthESSA Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EPIX. Previous Next 1.1 News and Social Media Coverage News SentimentESSA Pharma has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ESSA Pharma this week, compared to 0 articles on an average week.Search Interest3 people have searched for EPIX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ESSA Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,566.00 in company stock.Percentage Held by Insiders14.70% of the stock of ESSA Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.12% of the stock of ESSA Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ESSA Pharma's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ESSA Pharma are expected to decrease in the coming year, from ($0.80) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ESSA Pharma is -10.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ESSA Pharma is -10.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioESSA Pharma has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ESSA Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About ESSA Pharma Stock (NASDAQ:EPIX)ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Read More EPIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EPIX Stock News HeadlinesMay 10, 2024 | americanbankingnews.comESSA Pharma (NASDAQ:EPIX) Shares Pass Below 50 Day Moving Average of $7.91April 9, 2024 | finance.yahoo.comESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceMay 10, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 9, 2024 | prnewswire.comESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 8, 2024 | finance.yahoo.comESSA Pharma (NASDAQ:EPIX) Is In A Strong Position To Grow Its BusinessApril 7, 2024 | investing.comEssa Pharma COO sells shares worth over $5,500April 5, 2024 | morningstar.comESSA Pharma Inc EPIXMarch 10, 2024 | finance.yahoo.comEPIX Jul 2024 7.500 callMay 10, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 10, 2024 | finance.yahoo.comEPIX Jul 2024 12.500 putMarch 7, 2024 | prnewswire.comESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERSFebruary 13, 2024 | benzinga.comESSA Pharma: Q1 Earnings InsightsFebruary 13, 2024 | finance.yahoo.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023February 8, 2024 | finance.yahoo.comESSA Pharma Inc Executive Peter Virsik Sells 72,782 SharesFebruary 6, 2024 | finance.yahoo.comESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 22, 2024 | finance.yahoo.comESSA Pharma Inc.'s (NASDAQ:EPIX) hedge funds investors lost 12% last week but have benefitted from longer-term gainsDecember 20, 2023 | finance.yahoo.comEPIX: Initial Data from Combination Trial of Masofaniten and Enzalutamide Expected in 2024…December 14, 2023 | benzinga.comESSA Pharma Stock (NASDAQ:EPIX) Earnings Dates and Earning CallsDecember 12, 2023 | benzinga.comESSA Pharma Stock (NASDAQ:EPIX) Dividends: History, Yield and DatesDecember 12, 2023 | benzinga.comRecap: ESSA Pharma Q4 EarningsDecember 12, 2023 | finance.yahoo.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023December 11, 2023 | finance.yahoo.comBullish ESSA Pharma Insiders Loaded Up On US$1.19m Of StockNovember 24, 2023 | msn.comESSA Pharma director Franklin Berger buys common shares worth ~$133.3KNovember 21, 2023 | finance.yahoo.comESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare ConferenceNovember 8, 2023 | finance.yahoo.comESSA Pharma to Present at the Jefferies London Healthcare ConferenceOctober 31, 2023 | finance.yahoo.comWe Think ESSA Pharma (NASDAQ:EPIX) Can Afford To Drive Business GrowthOctober 30, 2023 | finance.yahoo.comEPIX: Dose Escalation Data for Combination of Masofaniten (EPI-7386) and Enzalutamide Presented at PCF Retreat…See More Headlines Receive EPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today5/10/2024Next Earnings (Estimated)5/14/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EPIX CUSIPN/A CIK1633932 Webwww.essapharma.com Phone778-331-0962Fax604-738-4080Employees50Year FoundedN/APrice Target and Rating Average Stock Price Target$16.50 High Stock Price Target$17.00 Low Stock Price Target$16.00 Potential Upside/Downside+165.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-17.41% Return on Assets-17.04% Debt Debt-to-Equity RatioN/A Current Ratio40.74 Quick Ratio40.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.30 per share Price / Book1.88Miscellaneous Outstanding Shares44,240,000Free Float37,737,000Market Cap$275.17 million OptionableOptionable Beta1.76 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. David Ross Parkinson M.D. (Age 74)President, CEO & Director Comp: $814.15kMr. David S. Wood C.M.A. (Age 67)CPA, CMA, CPA, M.B.A., MBA, Chief Financial Officer Comp: $590.39kMr. Peter A. Virsik M.B.A. (Age 53)M.S., Executive VP & COO Comp: $645.95kDr. Alessandra Cesano M.D. (Age 63)Ph.D., Chief Medical Officer & Executive VP Comp: $623.93kChandtip ChandhasinExecutiveErica OsbourneExecutiveErin RudsinskiExecutiveLoleta HarrisExecutiveNeil ThaparExecutiveNkengyal BarberExecutiveMore ExecutivesKey CompetitorsNanobiotixNASDAQ:NBTXFibroBiologicsNASDAQ:FBLGAquestive TherapeuticsNASDAQ:AQSTProcaps GroupNASDAQ:PROCAkebia TherapeuticsNASDAQ:AKBAView All CompetitorsInsiders & InstitutionsPeter VirsikSold 694 sharesTotal: $4,823.30 ($6.95/share)BNP Paribas Financial MarketsSold 14,971 shares on 5/1/2024Ownership: 0.096%Peter VirsikSold 694 sharesTotal: $5,510.36 ($7.94/share)Peter VirsikSold 694 sharesTotal: $6,232.12 ($8.98/share)PFM Health Sciences LPSold 936,753 shares on 2/15/2024Ownership: 7.388%View All Insider TransactionsView All Institutional Transactions EPIX Stock Analysis - Frequently Asked Questions Should I buy or sell ESSA Pharma stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EPIX shares. View EPIX analyst ratings or view top-rated stocks. What is ESSA Pharma's stock price target for 2024? 2 brokers have issued 12-month price targets for ESSA Pharma's shares. Their EPIX share price targets range from $16.00 to $17.00. On average, they expect the company's stock price to reach $16.50 in the next year. This suggests a possible upside of 176.4% from the stock's current price. View analysts price targets for EPIX or view top-rated stocks among Wall Street analysts. How have EPIX shares performed in 2024? ESSA Pharma's stock was trading at $6.60 at the start of the year. Since then, EPIX shares have decreased by 9.5% and is now trading at $5.97. View the best growth stocks for 2024 here. Are investors shorting ESSA Pharma? ESSA Pharma saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 926,500 shares, an increase of 20.4% from the April 15th total of 769,300 shares. Based on an average daily trading volume, of 105,900 shares, the short-interest ratio is currently 8.7 days. View ESSA Pharma's Short Interest. When is ESSA Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our EPIX earnings forecast. How were ESSA Pharma's earnings last quarter? ESSA Pharma Inc. (NASDAQ:EPIX) posted its earnings results on Tuesday, February, 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.03. What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include RedHill Biopharma (RDHL), Aurinia Pharmaceuticals (AUPH), Lipocine (LPCN), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Agile Therapeutics (AGRX), Biopharmx (BPMX), Corbus Pharmaceuticals (CRBP) and Heat Biologics (HTBX). Who are ESSA Pharma's major shareholders? ESSA Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BNP Paribas Financial Markets (0.10%). Insiders that own company stock include David Ross Parkinson, Franklin M Berger, Growth N V Biotech and Peter Virsik. View institutional ownership trends. How do I buy shares of ESSA Pharma? Shares of EPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EPIX) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressMissed NVDA? Buy this AI stock NOWChaikin AnalyticsGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
